Major Trials On Dual-Antiplatelet Therapy For DES In The Works
This article was originally published in The Gray Sheet
Executive Summary
The four major drug-eluting stent manufacturers are negotiating the design of a clinical trial that will help determine the optimal duration of concomitant dual-antiplatelet therapy for patients with a drug-eluting stent, according to Boston Scientific
You may also be interested in...
High Hopes For Stent Antiplatelet Therapy Trial
FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents
High Hopes For Stent Antiplatelet Therapy Trial
FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents
High Hopes For Stent Antiplatelet Therapy Trial
Planned $100 million, 30-month study aims to allay stent safety concerns, guide anti-platelet good practice .